We would love to hear your thoughts about our site and services, please take our survey here.
Good Post alamo55. Although a few have taken profits recently, I say good luck to them. I on the other hand want a lot more and I am convinced I will make a fortune on Dest with my large holding.
I am convinced this sell off will be short lived as their are 2 bits of news that could drop anytime this month. Firstly an update on the trial that NIAID of USA are doing and I am expecting just as good data on that as we got yesterday. Secondly the biggie update on partnering news for XF-73. As you can see from alamo's post below, this line says it all
''Active discussions are progressing at various stages with a number of interested global parties having access to the XF-73 data''. Note the word GLOBAL PARTIES. I have been saying for a while now that GSK and PFIZER are interested and both are GLOBAL pharma. Just imagine what this will do to the share price if those names are confirmed by the company.
I think Rene is primed and ready for it's next move up. The data will be available now and hopefully the company will be discussing with partners with a view to signing deals. Hoping for an Rns to update us on the findings of the data.
Let's hope it's our new Chairman loading up before the next news.
RNS landed as I predicted and WOW.
XF-73 dermal formulation was 100 times more effective at killing MRSA (USA 300 strain) than the topical antibiotic mupirocin, in two skin infection models. WOW and WOW.
Says the Kn@b who can't even get the name correct, lol. So many idiots on these boards who have not got a clue.
Your welcome OldDogg. Good luck for next week guy's, lets hope the Rns lands on Monday to set us up for the week.
The link below is the podcast by Justin, he thinks DEST could potentially could get to £8-9. I am very confident and would be very happy with £3-4 pound and that is very realistic in my opinion.
Listen from about 18 mins in.
https://t.co/DiK7uRrV4k
Saxondale you are not wrong. This is a quality pharma and some idiots seem to think this is a punt, the rerate hasn't even begun. Fair value is over a pound at least for now and I have been saying this could 5 to 10 bag in 12-18 months. How many companies have 2 phase 3 ready drugs both with Billion dollar markets and valued at a measly £40M Mcap. If this was on the Nasdaq it would be worth £200 -300M.
The reason I say the rerate hasn't begun is because:
1. expect an RNS tomorrow or Monday re the CMS trial in China.
2. Expect an update in August on the NIAID trial for USA army.
3. Expect an update in August/September re XF-73 partnership discussions. Rumors are that Pfizer and GSK are interested. Just imagine if the company confirm this, it will go mental.
Then we should be getting some revenue from the sales of Sporcov.
For those that are new to Dest, the trial data that I posted the other day is a trial that was done by our partner CMS in China.
It is for using XF-73 in Dermal, superficial skin infections.
The read across from this is that I am expecting just as good results from the NIAID trial in for wounds for the USA army.
I am expecting an RNS shortly to update us on this trial and another RNS in August to update on the NIAID trial.
I asked if we will be getting a Q2 update soon and the answer was the next news is likely to be the AD. That is why I said I think it will happen much sooner than end of Q3.
Just had it confirmed that the AD will be published by the end of Q3 and not tomorrow. Also government approval is not a condition for the AD to be published but the company would prefer to have it. Got the impression it will happen much sooner than end of Q3.
Won't surprise me if new Chairman has been buying. Would send a great message if he went over 3%.
This was published today, so likely get an Rns tomorrow.
Efficacy of a Novel Antibacterial Agent Exeporfinium Chloride, (XF-73), Against Antibiotic-Resistant Bacteria in Mouse Superficial Skin Infection Models.
Conclusion
F-73 is a new structurally distinct antimicrobial drug with a unique mechanism of action which has the potential to be an effective and safe candidate for the topical treatment of microbial infections. In this study, XF-73 was shown to have good in vitro activity against a number of S. aureus isolates, including multidrug-resistant strains, with efficacy superior or comparable to that of the concurrently tested antibacterial drugs; and the XF-73 dermal formulation also demonstrated effective inhibition of antibiotic-resistant bacteria in two models of superficial skin infection, including a high-level mupirocin-resistant strain that was virtually unresponsive to mupirocin. Preliminary morphological studies suggest that the unique mechanism of action of XF-73 may be related to an initial interaction with the bacterial cell wall, followed by a subsequent interaction with the the bacterial cell membrane which affects the cell membrane integrity which could increase its permeability, explaining the release of important intracellular components and ultimately bacterial death without causing bacterial lysis. However, the precise molecular mechanism of the interaction between XF-73 and bacterial membranes is not yet fully understood and will be the focus of future research.
This is what Justin Urquhart Stewart, city expert had to say about our new Chairman.
'He takes up roles at businesses where he can pick up significant shareholdings which will give him a windfall.
'His track record has been gaining the chairmanship of businesses where there's likely to be a corporate action – usually a sale – which means he'll be a swift beneficiary.
'Quite often you'll see he is the lightning rod for a corporate transaction to be carried out.'
You think Dest is punt? Find me another company that has 2 phase 3 ready drugs that have billion dollar markets, one licensed and major pharma showing an interest in the other with a Mcap of around £32M. If you can't see the opportunity here then ask yourself this, why would our new CEO be leaving an $8B company to join a £32M company?
I will apologise upfront for this post. I know many on here are suffering a big loss on their investment, as I am also. The aim of this post is to bring to your attention a company that I think will do very well and urge you to research it. The company is Destiny Pharma (Dest) and I have a substantial holding in it. I will give a few brief points about it.
1. It has 2 phase 3 ready drugs - one is licensed already and in discussions with partners for the other.
2. NIAID of USA is paying for pre clinical trials for one of the drugs XF-73 with a view for using it in wounds for the USA army.
3. Excellent results for Sporcov for Covid and influenza.
4. New CEO appointed - Was at GW Pharma that got taken over for $7.2B, currently at Jazz pharma $8.3B. Also worked for GSK. Why would he join a company that has a mcap of £29M.
5. I believe XF-73 will be standard of care for almost every operation in the future, try putting a price on that.
I won't bore you with anymore, but feel free to come to the Dest chat and ask any questions you may have. Once again apologies for this off topic post.
Justin sums it up nicely in the video below.
https://t.co/EK55zN44yc
Any idea what all those big trades are from Friday? Normally lucky to see a couple of trades.
Just going to put here what I am hearing, take it with a pinch of salt. The in vivo data is looking very good ( this was more or less confirmed in the recent presentation) and we are likely to sign 2 types of deals with interested parties. Now the interesting part is that we have partnerships with pharma companies that are likely to sign deals if the data is good enough, however a number of companies that do not have partnerships with us have also approached the company and want to see the data with a view to signing a deal. The deals will be either a technology platform partnership or we will license the platform.